Abstract
The gold standard for treatment of the antiphospholipid antibody syndrome (APS) after thrombosis remains high-intensity warfarin, and, in pregnancy, heparin and aspirin. Exciting developments include the potential role of hydroxychloroquine as a prophylactic drug, stem cell transplantation, and B-cell tolerance. Animal models appear to be a fruitful "proving ground" of new therapies. The introduction of revised classification criteria for APS should aid in appropriate characterization of, and selection of, patients for clinical trials.
MeSH terms
-
Abortion, Spontaneous / drug therapy
-
Abortion, Spontaneous / etiology
-
Antiphospholipid Syndrome / classification
-
Antiphospholipid Syndrome / complications
-
Antiphospholipid Syndrome / therapy*
-
Aspirin / therapeutic use
-
B-Lymphocytes / immunology
-
Hematopoietic Stem Cell Transplantation*
-
Heparin / therapeutic use
-
Humans
-
Immunization, Passive*
-
Injections, Intravenous
-
Plasmapheresis
-
Platelet Aggregation Inhibitors / therapeutic use
-
Thrombosis / drug therapy*
-
Thrombosis / etiology
-
Warfarin / therapeutic use
Substances
-
Platelet Aggregation Inhibitors
-
Warfarin
-
Heparin
-
Aspirin